BD and Lab21 Collaborate
News Oct 16, 2012
BD Diagnostics and Lab21 have announced that they will collaborate to develop oncology assays for the BD MAX™ fully automated, bench-top molecular system.
Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers.
BD will be responsible for manufacturing and commercializing the tests worldwide. The first two assays will be designed to detect mutations in the KRAS and BRAF genes.
These initial assays were selected because of their current importance in optimizing the management of cancer patients.
The agreement also includes the development of novel nucleic acid extraction procedures from formalin-fixed paraffin-embedded tissue.
The collaboration will develop BD’s first offering in personalized cancer diagnostics on the BD MAX system.
“When used in conjunction with other laboratory and clinical information, these assays will provide critical input to support oncologists and their patients in making more informed decisions about their care,” said Tom Polen, President, BD Diagnostics - Diagnostic Systems.
Graham Mullis, CEO of Lab21, added, “We are pleased to expand our partnership with BD from the detection of Aspergillus species to the broader development and commercialization of important diagnostic markers in the oncology area. Lab21 has significant experience with and proven assay development capability in cancer molecular diagnostics.”
Financial terms of the agreement and information regarding additional assays were not disclosed.
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018